Inhibition of Chk1 Kills Tetraploid Tumor Cells Through a P53-dependent Pathway
Overview
Authors
Affiliations
Tetraploidy constitutes an adaptation to stress and an intermediate step between euploidy and aneuploidy in oncogenesis. Tetraploid cells are particularly resistant against genotoxic stress including radiotherapy and chemotherapy. Here, we designed a strategy to preferentially kill tetraploid tumor cells. Depletion of checkpoint kinase-1 (Chk1) by siRNAs, transfection with dominant-negative Chk1 mutants or pharmacological Chk1 inhibition killed tetraploid colon cancer cells yet had minor effects on their diploid counterparts. Chk1 inhibition abolished the spindle assembly checkpoint and caused premature and abnormal mitoses that led to p53 activation and cell death at a higher frequency in tetraploid than in diploid cells. Similarly, abolition of the spindle checkpoint by knockdown of Bub1, BubR1 or Mad2 induced p53-dependent apoptosis of tetraploid cells. Chk1 inhibition reversed the cisplatin resistance of tetraploid cells in vitro and in vivo, in xenografted human cancers. Chk1 inhibition activated p53-regulated transcripts including Puma/BBC3 in tetraploid but not in diploid tumor cells. Altogether, our results demonstrate that, in tetraploid tumor cells, the inhibition of Chk1 sequentially triggers aberrant mitosis, p53 activation and Puma/BBC3-dependent mitochondrial apoptosis.
A link between mitotic defects and mitotic catastrophe: detection and cell fate.
Sazonova E, Petrichuk S, Kopeina G, Zhivotovsky B Biol Direct. 2021; 16(1):25.
PMID: 34886882 PMC: 8656038. DOI: 10.1186/s13062-021-00313-7.
GRP78/BiP determines senescence evasion cell fate after cisplatin-based chemotherapy.
Ei Z, Choochuay K, Tubsuwan A, Pinkaew D, Suksomtip M, Vinayanuwattikun C Sci Rep. 2021; 11(1):22448.
PMID: 34789798 PMC: 8599848. DOI: 10.1038/s41598-021-01540-8.
Targeting tumor cell senescence and polyploidy as potential therapeutic strategies.
Saleh T, Carpenter V, Bloukh S, Gewirtz D Semin Cancer Biol. 2020; 81:37-47.
PMID: 33358748 PMC: 8214633. DOI: 10.1016/j.semcancer.2020.12.010.
Galofre C, Gonul Geyik O, Asensio E, Wangsa D, Hirsch D, Parra C Cancers (Basel). 2020; 12(5).
PMID: 32365785 PMC: 7281619. DOI: 10.3390/cancers12051118.
Prognosis, Biology, and Targeting of Dysregulation in Multiple Myeloma.
Flynt E, Bisht K, Sridharan V, Ortiz M, Towfic F, Thakurta A Cells. 2020; 9(2).
PMID: 31991614 PMC: 7072230. DOI: 10.3390/cells9020287.